Glucotrack announces 180-day extension to regain compliance with nasdaq minimum bid price requirement

Rutherford, nj, nov. 30, 2023 (globe newswire) -- glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from nasdaq stock market llc (“nasdaq”) that the company has been granted an additional 180-day compliance period, or until may 20, 2024, to regain compliance with nasdaq's minimum bid price rule.
GCTK Ratings Summary
GCTK Quant Ranking